Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals

BACKGROUND: A vast majority of the commercially available lateral flow immunoassay (LFIA) is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based lateral flow immunoassay (LFIA) test was developed for quantitative measurement of the total binding antibody units (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Shurrab, Farah M., Younes, Nadin, Al-Sadeq, Duaa W., Liu, Na, Qotba, Hamda, Abu-Raddad, Laith J., Nasrallah, Gheyath K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882034/
https://www.ncbi.nlm.nih.gov/pubmed/35231609
http://dx.doi.org/10.1016/j.ijid.2022.02.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882034/
https://www.ncbi.nlm.nih.gov/pubmed/35231609
http://dx.doi.org/10.1016/j.ijid.2022.02.052

Ejemplares similares